To add to it: Convert our existing bulk inventor

To add to it:

Convert our existing bulk inventory of Excellagen Wound Conforming Gel Matrix into final fill finish and will be shipping product to AvMedical from our partners in England, BSM. We have enough existing bulk inventory to create approximately 25,000 syringes with 70% converted into our .08 cc syringes and 30% into our 3.0 cc syringes for larger wounds. This process is expected to take 60-90 days to have inventory in place to sale. We believe these runs will support our sales forecast up to approximately $30 million.
• We believe our forecast for this slimmed down focus on just VA will yield, at the end of month 12, an annualized run rate of approximately $10,000,000 while achieving a positive EBITDA in Month 6 of this rollout and an EBITDA projected north of 70%. Years 2 and 3 is forecasted to have $39 million and $92 million of revenue, respectfully, with EBITDA forecasted at $32 million and $65 million, respectfully.
• Begin our sales initiative with outsourced VA specialized sales groups.